SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-025945
Filing Date
2022-05-12
Accepted
2022-05-12 16:10:55
Documents
73
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0322_jasperthera.htm   iXBRL 10-Q 1285513
2 SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS, DATED MARCH 17, 2022, BY f10q0322ex10-6_jasperthera.htm EX-10.6 55332
3 CERTIFICATION f10q0322ex31-1_jasperthera.htm EX-31.1 9837
4 CERTIFICATION f10q0322ex31-2_jasperthera.htm EX-31.2 9827
5 CERTIFICATION f10q0322ex32-1_jasperthera.htm EX-32.1 7401
  Complete submission text file 0001213900-22-025945.txt   5292160

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE jspr-20220331.xsd EX-101.SCH 63238
7 XBRL CALCULATION FILE jspr-20220331_cal.xml EX-101.CAL 25112
8 XBRL DEFINITION FILE jspr-20220331_def.xml EX-101.DEF 233909
9 XBRL LABEL FILE jspr-20220331_lab.xml EX-101.LAB 503313
10 XBRL PRESENTATION FILE jspr-20220331_pre.xml EX-101.PRE 249281
67 EXTRACTED XBRL INSTANCE DOCUMENT f10q0322_jasperthera_htm.xml XML 515639
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39138 | Film No.: 22917899
SIC: 2836 Biological Products, (No Diagnostic Substances)